down arrow

Pharmanutra SpA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IT0005274094
EUR
53.00
-0.6 (-1.12%)

Dec 12

MIL

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Shedir Pharma Group SpA
Pharmanutra SpA
Enervit SpA
Laboratorio Farmaceutico Erfo SpA
Pierrel SpA
Why is Pharmanutra SpA ?
1
  • ROCE(HY) Lowest at 0%
  • INTEREST COVERAGE RATIO(Q) Lowest at 3,974.04
  • INVENTORY TURNOVER RATIO(HY) Lowest at 0%
2
With ROE of 26.95%, it has a Very Expensive valuation with a 7.51 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of -2.03%, its profits have risen by 16.9% ; the PEG ratio of the company is 1.7
3
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -2.03% returns in the last 1 year, the stock has also underperformed Italy FTSE MIB in each of the last 3 annual periods
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Pharmanutra SpA for you?

Medium Risk, Low Return

Absolute
Risk Adjusted
Volatility
Pharmanutra SpA
-1.3%
0.33
35.35%
Italy FTSE MIB
24.83%
1.34
19.25%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
18.11%
EBIT Growth (5y)
14.84%
EBIT to Interest (avg)
17.12
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.12
Sales to Capital Employed (avg)
1.21
Tax Ratio
39.63%
Dividend Payout Ratio
57.85%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
62.00%
ROE (avg)
28.41%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
7.51
EV to EBIT
17.33
EV to EBITDA
15.39
EV to Capital Employed
7.00
EV to Sales
3.83
PEG Ratio
1.65
Dividend Yield
0.02%
ROCE (Latest)
40.37%
ROE (Latest)
26.95%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Icon
Not enough Data to analyse Financial Trend
Icon
Not enough Data to analyse Financial Trend
Here's what is working for Pharmanutra SpA
Cash and Eqv
Highest at EUR 20.8 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio
Lowest at -50.73 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by -188.75% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Pharmanutra SpA
Interest Coverage Ratio
Lowest at 3,974.04
in the last five periods
MOJO Watch
The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Operating Profit
Lowest at EUR 4.13 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (EUR MM)

Operating Profit Margin
Lowest at 15.12 %
in the last five periods
MOJO Watch
Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit
Lowest at EUR 3.65 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (EUR MM)

Net Profit
Lowest at EUR 3.26 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (EUR MM)

Inventory Turnover Ratio
Lowest at 0%
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio
Lowest at 0%
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."